1824. Colorado’s Statewide Antimicrobial Stewardship (AMS) Collaborative Final Results: Facilitating Syndrome-Specific Interventions for Skin and Soft Tissue Infection (SSTI) and Urinary Tract Infection (UTI)
Session: Oral Abstract Session: Thinking Beyond Your Hospital: Stewardship on a Broader Scale
Saturday, October 7, 2017: 10:45 AM
Room: 01AB

Background: Colorado Hospital Association (CHA) led a statewide collaborative to engage hospitals in AMS, focused on interventions for UTI and SSTI. The collaborative goals were to reduce use of fluoroquinolones (FQs) for UTIs, increase the proportion of diagnosed UTIs meeting objective criteria, reduce exposure to antibiotics with broad gram negative activity for SSTI, and shorten treatment durations for UTI and SSTI. We evaluated the effect of the collaborative on these measures.

Methods: Diagnostic (UTI) and treatment guidance (UTI and SSTI) were developed by a local expert panel. Collaborative methodology was used to engage local hospital AMS teams in guideline implementation.  Teams submitted data for 80 cases during the baseline period (2014) and 20 cases per quarter during the intervention period (Oct 2015 – Dec 2016) for each condition.  Primary analyses were changes in trends of the main outcomes by interrupted time series analysis. Secondary analyses were the aggregate changes in the main outcomes between the baseline and intervention periods.

Results: 27 acute care hospitals (bed range 15–567) participated in the collaborative. Data were reported for 1530 UTI and 722 SSTI cases from the baseline period and for 2514 UTI and 1030 SSTI cases from the intervention. Interrupted time series analyses of the main outcomes are shown in the Figure. The trend in exposure to FQs for UTIs decreased significantly from baseline to the intervention (p = .03). Changes in the trends for the other outcomes did not reach statistical significance. In the secondary analyses, exposure to FQs declined from 49% at baseline to 40% during the intervention (UTI), and the proportion of diagnosed UTIs meeting objective criteria increased from 51% to 54% (p=0.10).  Among SSTI cases, exposure to antibiotics with broad gram-negative activity declined from 61% to 53% (p=0.001), and the median duration of therapy declined from 13 to 11 days (p<0.0001).

Conclusion: A statewide collaborative successfully engaged hospitals to participate in AMS. Intended changes in prescribing practices for the collaborative were observed; however, the degree of success varied by outcome. Additional work is needed to explore factors associated with success or lack thereof among the individual hospitals.

CHA 4 panel chart

Heidi Wald, MD, MSPH, University of Colorado School of Medicine, Aurora, CO, Teri Hulett, BSN, CIC, FAPIC, Colorado Hospital Association, Englewood, CO, Bryan Knepper, MPH, MS, CIC, Patient Safety and Quality, Denver Health Medical Center, Denver, CO, Gerard Barber, RPh, MPH, Department of Clinical Pharmacy, University of Colorado Hospital, Aurora, CO, Kati Shihadeh, PharmD, Acute Care Pharmacy, Denver Health Medical Center, Denver, CO, Marc Meyer, R.Ph, BPharm, CIC, Southwest Memorial Health System, Cortez, CO, John Hammer, MD, CarePoint Health, Denver, CO; Rose Medical Center, Denver, CO and Timothy C. Jenkins, MD, Denver Health, Denver, CO


H. Wald, Colorado Hospital Association: Consultant , Consulting fee

T. Hulett, Colorado Hospital Association: Consultant and Employee , Salary

B. Knepper, None

G. Barber, Merck: Speaker's Bureau , Speaker honorarium

K. Shihadeh, None

M. Meyer, None

J. Hammer, None

T. C. Jenkins, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.